KIT and esophageal squamous cell carcinoma: Importantly, all potential biomarkers, including c-Kit, for monitoring treatment responses to this regimen in patients with advanced ESCC, require additional observation and confirmation in randomized prospective trials with a larger sample size, which may allow further customization of treatments and prediction of individualized therapeutic responses.